Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
出版年份 2017 全文链接
标题
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 110, Issue 1, Pages 40-48
出版商
Oxford University Press (OUP)
发表日期
2017-05-30
DOI
10.1093/jnci/djx134
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
- (2017) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
- (2016) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
- (2016) Paul E. Goss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
- (2015) E.J. Blok et al. CANCER TREATMENT REVIEWS
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
- (2015) Jack Cuzick et al. LANCET ONCOLOGY
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
- (2014) Mustafa Al-Mubarak et al. PLoS One
- Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
- (2013) Jack Cuzick et al. LANCET
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
- (2012) Rakhshanda Layeequr Rahman et al. Cancers
- High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
- (2011) D.B.Y. Fontein et al. EJSO
- Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover
- (2011) Huan Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
- (2011) Cornelis JH van de Velde et al. LANCET
- Exemestane for Breast-Cancer Prevention in Postmenopausal Women
- (2011) Paul E. Goss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17
- (2008) J. N. Ingle et al. ANNALS OF ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started